Overall rank by patents
#5,437
Across all tracked assignees
USPTO PatentsView assignee record - 63 granted patents across 77 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: F03G (SPRING, WEIGHT, INERTIA OR LIKE MOTORS; MECHANICAL-POWER PRODUCING DEVICES OR MECHANISMS, NOT OTHERWISE PROVIDED FOR OR USING ENERGY SOURCES NOT OTHERWISE PROVIDED FOR).
The verdict
Exergyn holds 63 US patents across 77 technology areas, rank #5,437 of 50,000 tracked assignees.
Exergyn, Ltd. has been granted 63 US utility patents between 2015 and 2025, placing Exergyn, Ltd. at rank #5,437 across all assignees tracked by PlainPatent. This portfolio spans 77 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.3 claims per patent with primary concentration in F03G (SPRING, WEIGHT, INERTIA OR LIKE MOTORS; MECHANICAL-POWER PRODUCING DEVICES OR MECHANISMS, NOT OTHERWISE PROVIDED FOR OR USING ENERGY SOURCES NOT OTHERWISE PROVIDED FOR). As a Foreign Corporation, Exergyn, Ltd. is one of the broader-portfolio assignees in the PatentsView dataset. By volume, Exergyn sits between Century Technology (shenzhen) Corporation Limited (63 patents, rank #5,433) and Guangdong Huanengda Electrical Appliances Co., Ltd (63 patents, rank #5,441) - the closest US assignees by grant volume. The composite Innovation Score of 55.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 36 grants, compared with 27 in the 2015–2019 window, a +33% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Exergyn, Ltd.'s 11.3 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while a multi-domain presence across 77 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Exergyn, Ltd. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Century Technology (Shenzhen) Corporation Limited
63 patents
Diehl Aerospace GmbH
63 patents
DisplayLink (UK) Limited
63 patents
Envisics Ltd
63 patents
FLOSFIA INC.
63 patents
First Dome Corporation
63 patents
GLOBALFOUNDRIES U.S. 2 LLC
63 patents
GUANGDONG HUANENGDA ELECTRICAL APPLIANCES CO., LTD
63 patents
Exergyn, Ltd.
63 patents
What this shows Exergyn holds 63 patents at rank #5,437, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #5,437 in granted patent volume.
Other assignees with the most granted patents in Exergyn's primary technology class.
Exergyn's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
55 Top 7% higher than 93% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 4.8% |
| 2016 | 6 | 9.5% |
| 2017 | 3 | 4.8% |
| 2018 | 9 | 14.3% |
| 2019 | 6 | 9.5% |
| 2020 | 3 | 4.8% |
| 2021 | 7 | 11.1% |
| 2022 | 5 | 7.9% |
| 2023 | 10 | 15.9% |
| 2024 | 7 | 11.1% |
| 2025 | 4 | 6.3% |
Top 15 of 77 technology areas
Overall rank by patents
#5,437
Across all tracked assignees
55.3 out of 100
How to use this portfolio
Exergyn's 63 grants land it in the top 7% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.